Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwin Dreesen

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
Journal of Crohn'S & Colitis|August 6, 2021
New Tools for Therapeutic Drug Monitoring: Making Big Things out of Small PiecesErwin Dreesen
Therapeutic Drug Monitoring|March 19, 2019
Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory DiseasesErwin Dreesen, Ann Gils
Journal of Crohn'S & Colitis|March 24, 2017
Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?Erwin Dreesen, Ann Gils
The American Journal of Gastroenterology|July 16, 2025
Response to Dai et alYannick Hoffert, Erwin Dreesen
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 30, 2019
ReplyErwin Dreesen, Ann Gils
The Lancet. Gastroenterology & Hepatology|February 3, 2023
A personalised taper-to-target strategy with adalimumab in Crohn's diseaseErwin Dreesen, Bram Verstockt
Alimentary Pharmacology & Therapeutics|October 16, 2018
Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors' replyErwin Dreesen, Ann Gils
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 23, 2020
ReplyErwin Dreesen, Séverine Vermeire
Inflammatory Bowel Diseases|August 26, 2023
Therapeutic Drug Monitoring 2.0: Time to Assemble the PuzzleZhigang Wang, Erwin Dreesen
Current Opinion in Pharmacology|October 31, 2020
Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issuesZhigang Wang, Erwin Dreesen
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
Journal of Crohn'S & Colitis|August 6, 2021
New Tools for Therapeutic Drug Monitoring: Making Big Things out of Small PiecesErwin Dreesen
Therapeutic Drug Monitoring|March 19, 2019
Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory DiseasesErwin Dreesen, Ann Gils
Journal of Crohn'S & Colitis|March 24, 2017
Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?Erwin Dreesen, Ann Gils
The American Journal of Gastroenterology|July 16, 2025
Response to Dai et alYannick Hoffert, Erwin Dreesen
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 30, 2019
ReplyErwin Dreesen, Ann Gils
The Lancet. Gastroenterology & Hepatology|February 3, 2023
A personalised taper-to-target strategy with adalimumab in Crohn's diseaseErwin Dreesen, Bram Verstockt
Alimentary Pharmacology & Therapeutics|October 16, 2018
Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors' replyErwin Dreesen, Ann Gils
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 23, 2020
ReplyErwin Dreesen, Séverine Vermeire
Inflammatory Bowel Diseases|August 26, 2023
Therapeutic Drug Monitoring 2.0: Time to Assemble the PuzzleZhigang Wang, Erwin Dreesen
Current Opinion in Pharmacology|October 31, 2020
Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issuesZhigang Wang, Erwin Dreesen
Pageof 11